Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 34830289)

  • 1. Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice.
    Huang CC; Chou CA; Chen WY; Yang JL; Lee WC; Chen JB; Lee CT; Li LC
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palmitate aggravates proteinuria-induced cell death and inflammation via CD36-inflammasome axis in the proximal tubular cells of obese mice.
    Li LC; Yang JL; Lee WC; Chen JB; Lee CT; Wang PW; Vaghese Z; Chen WY
    Am J Physiol Renal Physiol; 2018 Dec; 315(6):F1720-F1731. PubMed ID: 30230367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions.
    Chen Y; Li Y; Wang Y; Wen Y; Sun C
    Metabolism; 2009 Dec; 58(12):1694-702. PubMed ID: 19767038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
    Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T
    EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory Antibodies against PCSK9 Reduce Surface CD36 and Mitigate Diet-Induced Renal Lipotoxicity.
    Byun JH; Lebeau PF; Platko K; Carlisle RE; Faiyaz M; Chen J; MacDonald ME; Makda Y; Yousof T; Lynn EG; Dickhout JG; Krepinsky JC; Weaver F; Igdoura SA; Seidah NG; Austin RC
    Kidney360; 2022 Aug; 3(8):1394-1410. PubMed ID: 36176646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREB/PPAR-
    Liu Y; Cheng F; Luo Y; Zhan Z; Hu P; Ren H; Tang H; Peng M
    Biomed Res Int; 2017; 2017():8234507. PubMed ID: 28770225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE
    Nasiri-Ansari N; Nikolopoulou C; Papoutsi K; Kyrou I; Mantzoros CS; Kyriakopoulos G; Chatzigeorgiou A; Kalotychou V; Randeva MS; Chatha K; Kontzoglou K; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
    Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress.
    Trnovska J; Svoboda P; Pelantova H; Kuzma M; Kratochvilova H; Kasperova BJ; Dvorakova I; Rosolova K; Malinska H; Huttl M; Markova I; Oliyarnyk O; Melcova M; Skop V; Mraz M; Stemberkova-Hubackova S; Haluzik M
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet.
    Xu L; Nagata N; Chen G; Nagashimada M; Zhuge F; Ni Y; Sakai Y; Kaneko S; Ota T
    BMJ Open Diabetes Res Care; 2019; 7(1):e000783. PubMed ID: 31749970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for tubular Na
    Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
    Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Porphyromonas gingivalis exacerbates the progression of fatty liver disease via CD36-PPARγ pathway.
    Ahn JS; Yang JW; Oh SJ; Shin YY; Kang MJ; Park HR; Seo Y; Kim HS
    BMB Rep; 2021 Jun; 54(6):323-328. PubMed ID: 34078528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory stress promotes the development of obesity-related chronic kidney disease via CD36 in mice.
    Yang P; Xiao Y; Luo X; Zhao Y; Zhao L; Wang Y; Wu T; Wei L; Chen Y
    J Lipid Res; 2017 Jul; 58(7):1417-1427. PubMed ID: 28536108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
    Aragón-Herrera A; Feijóo-Bandín S; Otero Santiago M; Barral L; Campos-Toimil M; Gil-Longo J; Costa Pereira TM; García-Caballero T; Rodríguez-Segade S; Rodríguez J; Tarazón E; Roselló-Lletí E; Portolés M; Gualillo O; González-Juanatey JR; Lago F
    Biochem Pharmacol; 2019 Dec; 170():113677. PubMed ID: 31647926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
    Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
    Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mangiferin Improved Palmitate-Induced-Insulin Resistance by Promoting Free Fatty Acid Metabolism in HepG2 and C2C12 Cells via PPAR
    Zhang Q; Kong X; Yuan H; Guan H; Li Y; Niu Y
    J Diabetes Res; 2019; 2019():2052675. PubMed ID: 30809553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats.
    Ala M; Khoshdel MRF; Dehpour AR
    Oxid Med Cell Longev; 2022; 2022():1197061. PubMed ID: 35126806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic Regulation of Peroxisome Proliferator-Activated Receptor Gamma Mediates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease.
    Hajri T; Zaiou M; Fungwe TV; Ouguerram K; Besong S
    Cells; 2021 May; 10(6):. PubMed ID: 34072832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy.
    Lee YH; Kim SH; Kang JM; Heo JH; Kim DJ; Park SH; Sung M; Kim J; Oh J; Yang DH; Lee SH; Lee SY
    Am J Physiol Renal Physiol; 2019 Oct; 317(4):F767-F780. PubMed ID: 31390268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
    Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L
    Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.